American Journal of Cardiology
Volume 82, Issue 1 , Pages 61-65 , 1 July 1998

Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible united states adults

  • Thomas J. Hoerger, PhD

      Affiliations

    • Research Triangle Institute, Research Triangle Park, North Carolina, USA
    • Corresponding Author InformationAddress for reprints: Thomas J. Hoerger, PhD, Center for Economics Research, Research Triangle Institute, 3040 Cornwallis Road, Research Triangle Park, North Carolina 27709
    • ,
  • Mohan V. Bala, PhD

      Affiliations

    • Centocor, Inc., Malvern, Pennsylvania, USA
    • ,
  • Jeremy W. Bray, MS

      Affiliations

    • Research Triangle Institute, Research Triangle Park, North Carolina, USA
    • ,
  • Timothy C. Wilcosky, PhD

      Affiliations

    • Research Triangle Institute, Research Triangle Park, North Carolina, USA
    • ,
  • John LaRosa, MD

      Affiliations

    • Tulane University Medical Center, New Orleans, Louisiana, USA

Received 5 December 1997 ,Revised 11 February 1998 ,Accepted 11 February 1998.

References 

  1. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention (CDC), National Center for Health Statistics. (Vital and health statistics, plan and operation of the third national health and nutrition examination survey, 1988–1994). (DHHS publication no. (PHS) 94-1308, series 1, No. 32 4-0485).
  2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA. 1993;269:3015–3023
  3. SAS Institute Inc (Statistical Software). Cary, NC: SAS Institute Inc; 1993;
  4. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki heart study (primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia—safety of treatment, changes in risk factors, and incidence of coronary heart disease). N Engl J Med. 1987;317:1237–1245
  5. The Lipid Research Clinics Investigators . The lipid research clinics coronary primary prevention trial—results of 6 years of post-trial follow-up. Arch Intern Med. 1992;152:1399–1410
  6. Haheim LL, Holme I, Hjermann I, Leren P. The predictability of risk factors with respect to incidence and mortality of myocardial infarction and total mortality. A 12-year follow-up of the Oslo Study, Norway. J Intern Med. 1993;234:17–24
  7. Scandinavian Simvastatin Survival Study Group . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease (the Scandinavian simvastatin survival study (4S)). Lancet. 1994;344:1383–1389
  8. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia (West of Scotland Coronary Prevention Study Group). N Engl J Med. 1995;333:1301–1307
  9. Hunninghake DB, Stein EA, Dujovne CA, Harris WS, Feldman EB, Miller VT, et al. The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. N Engl J Med. 1993;328:1214–1219
  10. Denke MA. Cholesterol-lowering diets (a review of the evidence). Arch Intern Med. 1995;155:17–26
  11. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute, National Cholesterol Education Program. Cholesterol lowering in the patient with coronary heart disease: physician monography. September 1997. (NIH Publication no. 97-3794).
  12. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease (factors limiting achievement of lipid goals). Am J Med. 1996;100:197–204
  13. Kellick KA, Burns K, McAndrew E, Haberl E, Hook N, Ellis A. Outcome monitoring of fluvastatin in a department of veterans affairs lipid clinic. Am J Cardiol. 1995;76:62A–64A
  14. Marcelino JJ, Feingold KR. Inadequate treatment with 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitors by health care providers. Am J Med. 1996;100:605–610
  15. Pasternak RC, Brown LE, Stone PH, Silverman DI, Gibson CM, Sacks FM. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and “normal” cholesterol levels. Ann Intern Med. 1996;125:529–540
  16. Pearson T, Laurora IM. Treatment success in the lipid treatment assessment project (L-TAP). Circulation. 1997;96:361

☆ This study was supported in part by Parke-Davis and Pfizer, Inc.

PII: S0002-9149(98)00227-6

American Journal of Cardiology
Volume 82, Issue 1 , Pages 61-65 , 1 July 1998

Article Tools